Latest News
Register for Cure SMA’s First National Disability Employment Awareness Month Webinar
October is National Disability Employment Awareness Month (NDEAM)! In its honor, Cure SMA is hosting our first NDEAM webinar where the audience will hear directly from adults living with SMA […]
Read More ›AveXis Issues Community Statement on FDA Filing for SMA Type I
AveXis has provided the following community statement on their FDA filing for SMA type I. Dear SMA Community, AveXis, a Novartis company, is pleased to let you know that we […]
Read More ›
AveXis Files for FDA Approval of Gene Therapy for Spinal Muscular Atrophy
Type I
AveXis, Inc., a Novartis company, today announced that they have filed for FDA approval of AVXS-101, a gene therapy that replaces the survival motor neuron 1 (SMN1) gene, which is […]
Read More ›North Carolina to Screen Newborns for SMA Through Early Check
Early Check, a new research study led by RTI International, is now available for newborn babies in North Carolina. Early Check is a free screening study designed to identify children […]
Read More ›Breakthrough Prize Awarded to Adrian Krainer and Frank Bennett for SMA Research Leading to Spinraza
Collaborators Adrian Krainer, of Cold Spring Harbor Laboratory, and C. Frank Bennett, from Ionis Pharmaceuticals, received the 2019 Breakthrough Prize in Life Sciences. They won for the development of the […]
Read More ›Cure SMA Receives Generous Funding from Luke 18:1 Foundation
Cure SMA would like to thank the Luke 18:1 Foundation for their generous donations to our equipment pool and research programs. The foundation’s generosity will provide support and hope to […]
Read More ›